AdAlta (ASX:1AD)

Executive Summary

AdAlta Limited (ASX:1AD) is an Australian clinical-stage biotechnology company developing next-generation cellular immunotherapies and protein-based therapeutics. Leveraging its proprietary i-body antibody-like protein platform and CAR-T cell technology, AdAlta targets solid cancers, fibrotic diseases, and infectious diseases. The company operates under an 'East to West' model, sourcing innovative candidates from Asia while conducting development and manufacturing in Australia. Founded in 2020 and publicly listed, AdAlta has raised approximately A$20 million and is advancing its lead i-body candidate AD-214 for fibrotic diseases, with preclinical data supporting its potential to inhibit fibrosis through a novel mechanism. The company's CAR-T programs aim to overcome challenges in solid tumor treatment by engineering T cells with enhanced tumor infiltration and persistence. With a lean operation of 10-50 employees, AdAlta emphasizes capital efficiency and strategic partnerships to advance its pipeline.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for AD-214 in fibrotic diseases65% success
• Q2 2027IND filing for lead CAR-T program in solid tumors75% success
• Q3 2026Potential partnership or licensing deal for i-body platform in Asia50% success